Gefitinib (ZD1839) is an EGFR first-generation inhibitor with oral activity that inhibits the EGFR 19 Del and L858R mutations. Gefitinib has antitumor activity and is used for the treatment of EGFR-mutated non-small-cell lung cancers. Gefitinib administration RESULTS in the development of the EGFR C797S resistance mutation.

Madecassic acid (L-fucopyranose) is extracted from the whole herb of Centella asiatica.

8-Acetoxypentadeca-1,9Z-diene-4,6-diyn-3-ol is a natural product from Centella asiatica